ArticleChemistry & biodiversity2026
Integrative Approach to Elucidate the Antidiabetic Efficacy of Cipadessa baccifera (Roth) Miq.: A Study Based on Metabolomics, Network Pharmacology, and Animal Models.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cipadessa baccifera (Roth) Miq. (Family- Meliaceae) has been traditionally used to treat various ailments, including diabetes. The present study aimed to validate the antidiabetic efficacy of C. baccifera using both in vitro and in vivo diabetic models, followed by a mechanistic evaluation. UPLC-Q-ToF/MS analysis, enzyme inhibition assays, and in silico studies were performed. Cytotoxicity and glucose uptake studies were conducted on MIN6 cell line. qRT‒PCR was carried to assess GLUT4 expression in adipocytes. Immunostaining was performed to examine the differential expression of pancreatic cell subtypes. UPLC-Q-ToF/MS analysis identified 93 compounds, of which 18 were further selected for in silico protein‒protein interaction (PPI) network analysis. PPI network and pathway enrichment analyses predicted that the PPARG, AKT1, SIRT1, and FOXO1 genes are key regulators in diabetes. The in vitro enzyme inhibition assay revealed significant inhibition by the 70% hydroethanolic extract. The mechanistic study showed notable upregulation of GLUT4 mRNA expression, which also supports the network analysis algorithm. The in vivo study demonstrated a significant decrease in blood glucose, insulin, and HbA1c levels in the treated model. Immunostaining revealed significant restoration of insulin and myosin expression. These combined results highlight the potential of C. baccifera as a valuable supplement for diabetes management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.